½ÃÀ庸°í¼­
»óǰÄÚµå
1511798

DNA ÇÕ¼º ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ¼­ºñ½º À¯Çüº°, ±æÀ̺°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

DNA Synthesis Market Size, Share & Trends Analysis Report By Service Type (Gene Synthesis, Oligonucleotide Synthesis), By Length, By Application (Research Development, Diagnostics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

DNA ÇÕ¼º ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 82¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀº ȯÀÚ Ä¡·á¸¦ °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â °³ÀÎ ¸ÂÃãÇü À¯Àüü ½ÃÄö½Ì¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ 2024-2030³â 15.30%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ DNA ÇÕ¼ºÀº Áúº´ ¸ð´ÏÅ͸µ, ½Å¾à °³¹ß ¹× ¾à¹°À¯ÀüüÇп¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÉ ¼ö ÀÖ´Â »ý¹°ÇÐÀû ¿¬±¸ Ȱµ¿¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ´É·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº COVID-19 °¨¿°°ú ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï Ä¡·á¸¦ À§ÇÑ mRNA ±â¹Ý ¹é½ÅÀÇ Ã¤Åÿ¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, mRNAÀÇ À¯¿ë¼ºÀº ÇÕ¼º DNA¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ COVID-19 ¿¬±¸ÀÇ ÁÖ¿ä ÃÊÁ¡Àº DNA ÇÕ¼º¿¡ ÀÖ½À´Ï´Ù. ÇÕ¼º DNA´Â ¸ðµç PCR ºÐ¼®¿¡ »ç¿ëµË´Ï´Ù. ȯÀÚ´Â »ùÇÿ¡ Á¸ÀçÇÒ ¼ö ÀÖ´Â À¯Àüü DNA¸¦ ½Äº°Çϱâ À§ÇØ DNA ÇÁ¶óÀ̸Ӹ¦ »ç¿ëÇØ¾ß ÇÕ´Ï´Ù.

È¿¼Ò °øÇÐÀÇ ¹ßÀüÀº È¿¼Ò DNA ÇÕ¼ºÀ» À§ÇÑ ´Ù¾çÇÑ Á¢±Ù¹ýÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. È¿¼Ò¸¦ »ç¿ëÇÏ¿© ÇÙ»êÀ» ÇÊ¿äÇÑ ¼ø¼­·Î ¿¬¼âÇÏ´Â °ÍÀ¸·Î, ³Î¸® Àû¿ëÇϱâ À§Çؼ­´Â ´õ ¸¹Àº ÃÖÀûÈ­°¡ ÇÊ¿äÇÕ´Ï´Ù. ¸¹Àº ½ÃÀå °ü°èÀÚµéÀÌ ÂªÀº ½Ã°£¿¡ È¿À²ÀûÀ¸·Î È¿¼Ò¸¦ »ý»êÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±â¼úÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 5¿ù Ribbon Biolabs´Â 10,000 ¿°±â½ÖÀÇ DNA ¼­¿­À» ÇÕ¼ºÇÏ´Â ÀÓ¹«¸¦ ¼³Á¤Çϰí 2021³â 12¿ù±îÁö 20,000 ¿°±â½ÖÀÇ DNA ºÐÀÚ¸¦ ÇÕ¼ºÇÏ´Â ÀÌÁ¤Ç¥¸¦ ´Þ¼ºÇß½À´Ï´Ù.

À¯ÀüÀÚ ÇÕ¼ºÀº ƯÁ¤ ´ºÅ¬·¹¿ÀƼµå ¼­¿­¿¡ ÀÇÇÑ Ç¥Àû µ¹¿¬º¯ÀÌ À¯µµ ¹× ¿øÇϴ ǥÇöÇü ¹ßÇöÀ» Á¶ÀýÇÏ´Â µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµË´Ï´Ù. À¯ÀüÀÚ ÇÕ¼ºÀº À¯Àü°øÇÐÀÇ ÁÖ¿ä ±âÃʸ¦ Çü¼ºÇϰí, ³ôÀº ƯÀ̼ºÀ» °¡Áø Ç×ü ´ÜÆíÀÇ °³¹ß·Î Ç×üÀÇ ¹üÀ§¿Í ǰÁúÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù.

¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼ºÀº ÇÊ¿äÇÑ °áÁ¤ÀûÀÎ ¼­¿­À» °¡Áø ºñ±³Àû ªÀº ÇÙ»ê Á¶°¢À» ½ÇÇè½Ç¿¡¼­ »ý»êÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ±â¼úÀº ¿øÇÏ´Â ¿°±â¼­¿­ÀÇ ¸ÂÃãÇü ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ ºü¸£°í Àú·ÅÇÏ°Ô ¾òÀ» ¼ö ÀÖ´Â ¸Å¿ì °­·ÂÇÑ ¹æ¹ýÀÔ´Ï´Ù. °¢ ±â¾÷Àº ´ºÅ¬·¹¿ÀƼµå ÇÕ¼º °úÁ¤À» Áö¿øÇϱâ À§ÇØ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ¶óÀ̺귯¸®¸¦ °í¾ÈÇØ³Â½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 7¿ù Ribbon Biolabs´Â ´Ù¾çÇÑ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ¶óÀ̺귯¸®¸¦ »ç¿ëÇÏ¿© ´ºÅ¬·¹¿ÀƼµå ºÐÀÚ¸¦ ÇÕ¼ºÇÏ´Â Ribbon BiolabsÀÇ ¹æ¹ý¿¡ ´ëÇÑ ¹Ì±¹ ƯÇ㸦 ÃëµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¹æ¹ýÀº ¹Ì¸® ±¸ÃàµÈ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀÌµå ¶óÀ̺귯¸®·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç, È¿À²ÀûÀÎ Á¢±ÙÀÌ °¡´ÉÇÕ´Ï´Ù.

DNA ÇÕ¼º ½ÃÀå º¸°í¼­ÀÇ ÇÏÀ̶óÀÌÆ®

  • ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ºÎ¹®Àº 2023³â ¾÷°è¿¡¼­ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ³ôÀº Á¡À¯À²Àº À¯ÀüüÇÐ ¿¬±¸, ¸ÂÃã ÀÇ·á, Áúº´ÀÇ À¯ÀüÀû ±â¹Ý¿¡ ´ëÇÑ ÀÌÇØ¿¡ ÃÊÁ¡À» ¸ÂÃß°í Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º ºÎ¹®Àº 2023³â ´õ Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. À¯ÀüÀÚ Áúȯ¿¡ ´ëÇÑ Àνİú ÀÌÇØ°¡ ³ô¾ÆÁö¸é¼­ Áø´Ü ¹× ÀáÀçÀû Ä¡·á ÁßÀç¿¡ ´ëÇÑ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵忡 ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ¿¬±¸°³¹ß ºÎ¹®Àº 2023³â 63.30%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ´Â Àü ¼¼°è¿¡¼­ ÁøÇà ÁßÀÎ ¿¬±¸¸¦ Áö¿øÇϱâ À§ÇØ DNA ÇÕ¼ºÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ºÏ¹Ì°¡ 2023³â 39.76%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ Áö¿ªÀº ÀÏ¹Ý ´ëÁßÀÇ ÀÎ½Ä Çâ»ó, ÀÇ·á ½Ã¼³ÀÇ °³¼±, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ ½ÃÀåÀÌ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå DNA ÇÕ¼º ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ÀûÀÎ ½ÃÀå Àü¸Á.
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • DNA ÇÕ¼º ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå DNA ÇÕ¼º ½ÃÀå : ¼­ºñ½º À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀåÀÇ ¼­ºñ½º À¯ÇüÀÇ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼­ºñ½º À¯Çüº°, 2018-2030³â
  • ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º
  • À¯ÀüÀÚ ÇÕ¼º

Á¦5Àå DNA ÇÕ¼º ½ÃÀå : ±æÀÌ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀåÀÇ ±æÀÌÀÇ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀåÀÇ ±Ô¸ð¿Í µ¿Ç⠺м®, ±æÀ̺°, 2018-2030³â
  • ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º
  • À¯ÀüÀÚ ÇÕ¼º

Á¦6Àå DNA ÇÕ¼º ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀåÀÇ ¿ëµµÀÇ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • ¿¬±¸°³¹ß
  • Áø´Ü
  • Ä¡·áÁ¦

Á¦7Àå DNA ÇÕ¼º ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ DNA ÇÕ¼º ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • ¹ÙÀÌ¿ÀÀǾàǰ¡¤Áø´Ü¾à ±â¾÷
  • Çмú Á¶»ç±â°ü
  • °è¾à Á¶»ç±â°ü

Á¦8Àå DNA ÇÕ¼º ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
    • ºÏ¹Ì ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷/°æÀïÀÇ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä/»óÀå±â¾÷
    • Thermo Fisher Scientific Inc.
    • Twist Bioscience
    • BIONEER CORPORATION
    • Eton Bioscience, Inc
    • LGC Biosearch Technologies
    • IBA Lifesciences GmbH
    • Eurofins Scientific
    • Integrated DNA Technologies, Inc.
    • Quintara Biosciences
    • GenScript
KSA 24.07.16

DNA Synthesis Market Growth & Trends:

The global DNA synthesis market size is expected to reach USD 8.26 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 15.30% from 2024 to 2030 owing to the rising focus on personalized genome sequencing that aids determine patient care. In addition, DNA synthesis has the capability to revolutionize biological research activities for widespread applications in disease monitoring, drug discovery, and pharmacogenomics.

The COVID-19 pandemic positively impacted the adoption of mRNA-based vaccines for the treatment of COVID-19 infection and different types of cancers. The utility of mRNA boosts the demand for synthetic DNA. Furthermore, a major focus of Covid-19 research is DNA synthesis. Synthetic DNA is used in all PCR analyses. Patients need to use a DNA primer to identify any genomic DNA that may be present in the sample.

Progress in enzyme engineering is boosting the development of different approaches for enzymatic DNA synthesis. It involves the use of enzymes to chain the nucleic acids together in the required sequence and requires further optimization for its widespread applications. Many market players are striving to devise novel technologies for efficient enzymatic production of nucleotides in the lowest turnaround time. For instance, in May 2021, Ribbon Biolabs set a mission of synthesizing DNA sequences of 10,000 base pairs and accomplished a milestone of a 20,000 base pair DNA molecule by December 2021.

Gene synthesis has a broad spectrum of applications in targeted mutagenesis with a specific sequence of nucleotides along with the regulation of a desired phenotypic expression. It forms the primary basis of genetic engineering, which has significantly leveraged the scope and quality of antibodies by the development of antibody fragments with high specificity.

Oligonucleotide synthesis is the laboratory-based production of relatively short fragments of nucleic acids in a required definitive sequence. The technique is an extremely robust practice that facilitates rapid and inexpensive access to the custom-made oligonucleotides of the desired sequence. Companies have devised their oligonucleotide libraries to aid their nucleotide synthesis processes. For instance, in July 2022, Ribbon Biolabs declared that it secured a U.S. Patent that comprises Ribbon Biolabs' method for the synthesis of a nucleotide molecule using a diverse library of oligonucleotides. The approach comprises a pre-built library of oligonucleotides for efficient access.

DNA Synthesis Market Report Highlights:

  • The oligonucleotide synthesis segment dominated the industry in 2023. The larger share of this segment can be attributed to the focus on genomics research, personalized medicine, and understanding the genetic basis of diseases.
  • The oligonucleotide synthesis segment dominated the market with the larger revenue share in 2023. The growing awareness and understanding of genetic disorders contribute to the demand for oligonucleotides in diagnostics & potential therapeutic interventions.
  • The research and development segment dominated the market with a share of 63.30% in 2023. This is due to the growing use of DNA synthesis to support ongoing research studies across the globe.
  • North America dominated the market and accounted for a 39.76% revenue share in 2023. The region experiences market growth due to heightened public awareness, robust medical facilities, and substantial R&D investments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service Type
    • 1.2.2. Length
    • 1.2.3. Application
    • 1.2.4. End-use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. DNA Synthesis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing application of DNA synthesis in clinical diagnostics
      • 3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
      • 3.2.1.3. Increasing public-private spending on genomics
      • 3.2.1.4. Technological advancements in gene editing technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with genomics research
      • 3.2.2.2. Lack of skilled professionals and research support in undeveloped countries
  • 3.3. DNA synthesis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. DNA Synthesis Market: Service Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global DNA Synthesis Market Service Type Movement Analysis
  • 4.3. Global DNA Synthesis Market Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
  • 4.4. Oligonucleotide synthesis
    • 4.4.1. Oligonucleotides synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Standard oligonucleotides synthesis
      • 4.4.2.1. Standard oligonucleotides synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Custom oligonucleotide synthesis
      • 4.4.3.1. Custom oligonucleotides synthesis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Gene synthesis
    • 4.5.1. Gene synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Custom gene synthesis
      • 4.5.2.1. Custom gene synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Gene library synthesis
      • 4.5.3.1. Gene library synthesis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNA Synthesis Market: Length Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global DNA Synthesis Market Length Movement Analysis
  • 5.3. Global DNA Synthesis Market Size & Trend Analysis, by Length, 2018 to 2030 (USD Million)
  • 5.4. Oligonucleotide synthesis
    • 5.4.1. Oligonucleotides synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Less than 50nt
      • 5.4.2.1. Less than 50nt market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. 51-100nt
      • 5.4.3.1. 51-100nt market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. 101-150nt
      • 5.4.4.1. 101-150nt synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. More than 150nt
      • 5.4.5.1. More than 150nt synthesis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Gene synthesis
    • 5.5.1. Gene synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Less than 500nt
      • 5.5.2.1. Less than 500nt market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. 501-1000nt
      • 5.5.3.1. 501-1000nt market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. 1001-1500nt
      • 5.5.4.1. 1001-1500nt synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. 1501-2000nt
      • 5.5.5.1. 1501-2000nt synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. 2001-2500nt
      • 5.5.6.1. 2001-2500nt synthesis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.7. More than 2500nt
      • 5.5.7.1. More than 2500nt synthesis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNA Synthesis Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global DNA Synthesis Market Application Movement Analysis
  • 6.3. Global DNA Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Research & Development
    • 6.4.1. Research & development market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Oligonucleotide synthesis
      • 6.4.2.1. Oligonucleotide synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. PCR
      • 6.4.2.2.1. PCR synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. NGS
      • 6.4.2.3.1. NGS synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. CRISPR
      • 6.4.2.4.1. CRISPR synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.5. Cloning and mutagenesis
      • 6.4.2.5.1. Cloning and mutagenesis synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.6. Others
      • 6.4.2.6.1. Others synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Gene synthesis
      • 6.4.3.1. Gene synthesis market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.2. Synthetic biology
      • 6.4.3.2.1. Synthetic biology tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.3. Vaccine development
      • 6.4.3.3.1. Vaccine development synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.4. Genetic engineering
      • 6.4.3.4.1. Genetic engineering synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.5. Others
      • 6.4.3.5.1. Others synthesis tumors market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Diagnostics
    • 6.5.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Therapeutics
    • 6.6.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. RNAi therapies
      • 6.6.2.1. RNAi therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Antisense and oligonucleotide-based therapies
      • 6.6.3.1. Antisense and oligonucleotide-based therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNA Synthesis Market: End-Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global DNA Synthesis Market End-use Movement Analysis
  • 7.3. Global DNA Synthesis Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 7.4. Biopharmaceutical & Diagnostic Companies
    • 7.4.1. Biopharmaceutical & diagnostic companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Academic & Research Institutes
    • 7.5.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Contract Research Organizations
    • 7.6.1. Contract Research Organizations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. DNA Synthesis Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.9. Denmark
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. Mexico
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Argentina
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Competitive scenario
      • 8.7.4.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Twist Bioscience
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. BIONEER CORPORATION
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Eton Bioscience, Inc
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. LGC Biosearch Technologies
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. IBA Lifesciences GmbH
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Eurofins Scientific
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Integrated DNA Technologies, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Quintara Biosciences
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. GenScript
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦